Antifibrinolytic therapy in surgery for congenital heart disease

Area of Science:

• Cardiology
• Pharmacology
• Pediatric Surgery

Background:

• Adult cardiac surgery patients benefit from antifibrinolytic therapy to reduce bleeding and transfusions.
• Children undergoing cardiac surgery are at high risk for bleeding, but antifibrinolytic therapy risks and benefits are less understood.
• Existing literature on antifibrinolytics in pediatric congenital heart surgery is variable, making quantitative analysis difficult.

Purpose of the Study:

• To qualitatively review the literature on antifibrinolytic therapy in pediatric cardiac surgery.
• To assess the efficacy and safety of aprotinin, epsilon-aminocaproic acid, and tranexamic acid in children.
• To identify areas for future research regarding antifibrinolytic use in pediatric cardiac surgery.

Main Methods:

• Qualitative review of existing literature on antifibrinolytic therapy in congenital heart surgery.
• Analysis of studies examining aprotinin, epsilon-aminocaproic acid, and tranexamic acid in pediatric populations.
• Assessment of reported bleeding, transfusion rates, and adverse events.

Main Results:

• Significant support for the efficacy of all three drugs in decreasing bleeding and transfusion in pediatric cardiac surgery.
• Potential for greater benefit in specific pediatric populations.
• Limited data suggest similar efficacy among the drugs, with aprotinin possibly offering unique anti-inflammatory benefits.
• Insufficient evidence to conclude on safety; aprotinin anaphylaxis risk may be lower in children than adults.
• Variable and often pharmacologically unsound dosing schemes have been used.

Conclusions:

• Antifibrinolytic therapy is likely effective for reducing bleeding and transfusions in pediatric cardiac surgery.
• Further research is crucial to establish safety, determine relative efficacy, identify specific patient groups who benefit most, and optimize dosing strategies.